Company Background
Eden Biodesign is an integrated biopharmaceutical development organization and part of Watson Pharmaceuticals, Inc. Watson Pharmaceuticals, Inc. (NYSE-WPI) is a global specialty pharmaceutical company with approximately $3.6 billion in revenues in 2010, a broad product line and operations in well-established and emerging markets. Watson is focused on enhancing its commercial position in global generics, brands and biologic pharmaceutical products, targeting products that will deliver long-term growth while maintaining a competitive cost structure.
Eden Biodesign is designated as Watson’s Centre of Excellence for Biologics, delivering process and product development; cGMP manufacturing of biologics and quality/regulatory expertise from a custom-designed facility located in Liverpool, UK.
With well over a decade of experience in producing a wide range of complex biopharmaceuticals, Eden Biodesign provides Watson with a strong foundation for establishing a leadership position in global biologics.
Eden Biodesign is currently developing biosimilar versions of complex biopharmaceuticals, such as recombinant Follicle Stimulating Hormone (rFSH) which was in-licensed in July 2010.
Development of biosimilar products, “biobetters” and innovative biologics requires a level of expertise that can only be built on long experience and a successful history. Eden Biodesign has an enviable track record based on dozens of successful development projects undertaken for third party partners ranging from start-up biotechnology companies to multinational pharmaceutical companies.
It stands to reason that if you don’t know where you are going, you’ll have trouble getting there. And we’ve learned that to succeed in biopharmaceutical development it’s vital to “begin with the end in mind”.
We understand exactly how process development and clinical manufacturing fit into the broader picture of clinical development and have an intimate knowledge of global regulations and what it takes to bring a product to international markets. As individuals, and as a team, we have taken biopharmaceuticals from early concept studies all the way to successful market approval.
The combination of Eden Biodesign’s substantial intellectual capital, world-class development and manufacturing technologies, state-of-the-art facilities and significant market expertise, coupled with Watson Pharmaceuticals’ leading expertise in commercialisation of both generic and branded pharmaceuticals makes us your partner of choice for development of biologics.
To find out more information about Eden Biodesign, please contact us to request a copy of our brochure. If you would like one of our team to get in touch, please submit your details via our 
